PCM
FOLD

Palisade Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Palisade Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-14,000
Closed -$211K – 462
2018
Q1 		$211K Buy
+14,000
New +$213K 0.01% 428

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Palisade Capital Management's FOLD Position: Q2 2018 in Review

Palisade Capital Management sold out of Amicus Therapeutics (FOLD) in Q2 2018, closing a stake of 14,000 shares — an estimated $211K sold.

Palisade Capital Management first reported a position in FOLD in Q1 2018 and held it in 1 quarter. The position peaked at $211K in Q1 2018. 200 funds tracked by Wall St. Rank hold FOLD as of Q2 2018.

  • Palisade Capital Management reported no remaining Amicus Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Palisade Capital Management sold 14,000 Amicus Therapeutics shares in Q2 2018, an estimated $211K.
  • Palisade Capital Management first reported a position in Amicus Therapeutics in Q1 2018 and held it in 1 quarter.
  • Palisade Capital Management's Amicus Therapeutics position peaked at $211K in Q1 2018.
  • 200 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2018.

Based on Palisade Capital Management's 13F filing for Q2 2018, filed 13 Aug 2018.